Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	17.45B
Revenue (ttm)	2.40B
Net Income (ttm)	49.24M
Shares Out	1.60B
EPS (ttm)	0.03
PE Ratio	354.33
Forward PE	50.16
Dividend	0.03 (0.27%)
Ex-Dividend Date	Jan 9, 2026

Volume	32,453,340
Average Volume	17,143,729
Open	10.95
Previous Close	10.91
Day's Range	10.94 - 11.34
52-Week Range	9.70 - 14.25
Beta	0.49
RSI	32.76
Earnings Date	Mar 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.